Gov. Wes Moore (D), who calls quantum computing a “lighthouse industry” for Maryland, has secured more than $1 billion in ...

A team of researchers at Queen's University has developed a powerful new kind of computing machine that uses light to take on ...

The deal marks the latest collaboration between the two pharmaceutical giants, boosting AstraZeneca’s investment in the growing obesity market dominated by Western competitors. AstraZeneca will ...

The ink was barely dry on AstraZeneca’s announcement of a landmark investment in its Chinese capabilities before the U.K.-based pharma agreed to pay more than $1 billion to one of its regional ...

AstraZeneca is already deeply embedded in China's pharma sector, and is hungry for more, pledging $15 billion to an investment programme in the country and signing a mammoth licensing deal with Hong ...

AstraZeneca is expanding its prospects in cardiometabolic disease, paying $1.2 billion to begin a partnership on eight programs that include obesity drug candidates with potential advantages over ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. If you are wondering whether CSPC Pharmaceutical Group is still fairly priced ...

AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceutical. The ...

AstraZeneca and CSPC Pharmaceuticals collaborate on eight programs for obesity and type 2 diabetes, combining CSPC's AI-driven technologies with AstraZeneca's global reach. The partnership includes a ...

AstraZeneca AZN0.89%increase; green up pointing triangle said it entered into a collaboration agreement with China’s CSPC Pharmaceuticals to gain rights to a portfolio of early-stage experimental ...

SHANGHAI, Jan 30 (Reuters) - AstraZeneca (AZN.L), opens new tab will license experimental drugs for obesity and weight-related conditions from CSPC Pharmaceutical Group (1093.HK), opens new tab and ...

AstraZeneca and CSPC Pharmaceuticals have announced a new collaboration agreement for the development of therapies for obesity and type 2 diabetes. The agreement spans eight programmes, four of which ...